Alternately, in prostate cancer, butyrate has been shown to accelerate tumor progression by inducing autophagy and upregulating the chemokine CCL20 through TLR3 signaling, ultimately recruiting M2-like macrophages that support immune suppression [47]. Here, TLR3 is linked to neoplasm.